Cardiol Therapeutics (CRDL) Capital Expenditures (2020 - 2026)
Cardiol Therapeutics (CRDL) posted Capital Expenditures of -$34699.3 for Q1 2026, down 205.47% on a QoQ basis from $32899.9 in Q4 2025, and down 317.03% year-over-year from $15987.9 in Q1 2025.
Cardiol Therapeutics (CRDL) Capital Expenditures (2020 - 2026) Analysis & Trends
Cardiol Therapeutics' Capital Expenditures history runs 7 years deep, the most recent figure standing at -$34699.3 for Q1 2026.
- Quarterly Capital Expenditures fell 317.03% year-over-year to -$34699.3 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8639.4 (down 193.87% YoY) and the FY2025 annual result came in at $17557.1, up 15.2% from the prior year.
- Capital Expenditures was -$34699.3 for Q1 2026 at Cardiol Therapeutics, down from $32899.9 in the prior quarter.
- Across five years, Capital Expenditures topped out at $86615.0 in Q4 2023 and bottomed at -$34699.3 in Q1 2026.
- A 5-year average of $5808.7 and a median of -$2896.7 in 2023 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2022 — Capital Expenditures jumped 265.19% — and 2026, when it plunged 317.03%.
- Cardiol Therapeutics' Capital Expenditures stood at $74840.2 in 2022, then gained by 15.73% to $86615.0 in 2023, then plunged by 69.9% to $26071.9 in 2024, then grew by 26.19% to $32899.9 in 2025, then slumped by 205.47% to -$34699.3 in 2026.
- Business Quant data shows CRDL's Capital Expenditures at -$34699.3 in Q1 2026, $32899.9 in Q4 2025, and -$2193.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 168.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 110.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.95 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 99.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 39.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 51.00 Mn |
| 10 | Cardiol Therapeutics | 134.05 Mn | 134.05 Mn | - | -34,699.25 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34,699.25 |
| Mar 31, 2026 | -34,699.25 |
| Dec 31, 2025 | 32,899.92 |
| Dec 31, 2025 | 32,899.92 |
| Sep 30, 2025 | -2,192.98 |
| Sep 30, 2025 | -2,192.98 |
| Jun 30, 2025 | -4,647.11 |
| Jun 30, 2025 | -4,647.11 |
| Mar 31, 2025 | -8,320.49 |
| Mar 31, 2025 | -8,320.49 |
| Dec 31, 2024 | 26,071.94 |
| Dec 31, 2024 | 26,071.94 |
| Sep 30, 2024 | -5,769.86 |
| Sep 30, 2024 | -5,769.86 |
| Jun 30, 2024 | -2,778.33 |
| Jun 30, 2024 | -2,778.33 |
| Mar 31, 2024 | -2,567.71 |
| Mar 31, 2024 | -2,567.71 |
| Dec 31, 2023 | 86,614.96 |
| Dec 31, 2023 | 86,614.96 |